This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): hMPV/PIV-3/RSV Vaccine, MEDI534
Description: The vaccine was developed using an attenuated parainfluenza virus type-3 (PIV-3). Data from preclinical studies indicate that the vaccine protects against both RSV and PIV-3.
Deal Structure: MEDI-534 was originally developed by MedImmune; in June 2007, AstraZeneca closed its acquisition of MedImmune.
Additional information available to subscribers only: